William Blair Analysts Reduce Earnings Estimates for BMY

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Investment analysts at William Blair cut their Q2 2025 earnings per share (EPS) estimates for Bristol-Myers Squibb in a research note issued on Tuesday, April 15th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $1.57 for the quarter, down from their prior forecast of $1.61. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.74 per share. William Blair also issued estimates for Bristol-Myers Squibb's Q1 2026 earnings at $1.56 EPS, Q2 2026 earnings at $1.56 EPS, Q3 2026 earnings at $1.63 EPS, Q4 2026 earnings at $1.59 EPS and FY2026 earnings at $6.35 EPS.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%.

Other research analysts also recently issued reports about the company. Wells Fargo & Company boosted their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Cantor Fitzgerald upped their price objective on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. UBS Group cut their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Finally, Citigroup raised their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $57.67.

Bristol-Myers Squibb Trading Down 1.3 %

NYSE BMY opened at $49.33 on Thursday. The company has a 50 day moving average price of $57.24 and a 200 day moving average price of $56.68. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The firm has a market cap of $100.37 billion, a PE ratio of -11.16, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41.

Hedge Funds Weigh In On Bristol-Myers Squibb

A number of hedge funds have recently modified their holdings of BMY. Wealthspire Advisors LLC increased its position in shares of Bristol-Myers Squibb by 0.6% during the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock valued at $1,622,000 after acquiring an additional 170 shares during the last quarter. Edmp Inc. raised its position in Bristol-Myers Squibb by 0.4% in the fourth quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company's stock valued at $2,353,000 after purchasing an additional 171 shares during the period. Trust Point Inc. grew its stake in shares of Bristol-Myers Squibb by 1.9% in the fourth quarter. Trust Point Inc. now owns 9,423 shares of the biopharmaceutical company's stock valued at $533,000 after buying an additional 172 shares in the last quarter. Bedel Financial Consulting Inc. lifted its stake in Bristol-Myers Squibb by 3.2% during the 4th quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock worth $340,000 after acquiring an additional 175 shares in the last quarter. Finally, Horst & Graben Wealth Management LLC raised its stake in shares of Bristol-Myers Squibb by 2.4% in the fourth quarter. Horst & Graben Wealth Management LLC now owns 7,538 shares of the biopharmaceutical company's stock valued at $426,000 after acquiring an additional 179 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,823 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.07% of the stock is owned by insiders.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.03%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.